Volume 6 Issue 1
Jun.  2022
Turn off MathJax
Article Contents
Article Navigation >  Blood&Genomics  > 2022  >  6(1): 63-68
Xinxia Chang, Yingjia Zhou, Yufei Wang, Wenwen Zhao, Xiao Zhang. Effects of two different nutrition supply methods on improving hybridoma cell production[J]. Blood&Genomics, 2022, 6(1): 63-68. doi: 10.46701/BG.2022012022007
Citation: Xinxia Chang, Yingjia Zhou, Yufei Wang, Wenwen Zhao, Xiao Zhang. Effects of two different nutrition supply methods on improving hybridoma cell production[J]. Blood&Genomics, 2022, 6(1): 63-68. doi: 10.46701/BG.2022012022007
shu

Effects of two different nutrition supply methods on improving hybridoma cell production

doi: 10.46701/BG.2022012022007
  • 1.

    Key Laboratory of Antibody Technique of National Health Commission, Jiangsu Province Engineering Research Center of Antibody Drug, School of Basic Medicine, Nanjing Medical University, Nanjing, Jiangsu 211166, China

  • 2.

    Department of Geriatrics, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, China

  • 3.

    School of Stomatology, Nanjing Medical University, Nanjing, Jiangsu 211166, China

More Information
  • Corresponding author: Xiao Zhang, Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, 101 Longmian Avenue, Nanjing, Jiangsu 211166, China. E-mail: zhangxiao@njmu.edu.cn
  • Received Date: 2022-04-06
  • Rev Recd Date: 2022-06-02
  • Accepted Date: 2022-06-13
    • Available Online: 2022-07-08
  • Publish Date: 2022-06-30
    Abstract
  • Hybridoma cells are featured by the effective utilization of both B lymphocytes and immortalized myeloma cells, allowing for the continuous generation of monoclonal antibodies specific to antigens. With regard to conventional hybridoma technology, B lymphocytes must be fused with myeloma cells using various methods to generate hybridoma cells. Nutrition plays an important role in hybridoma cell survival and amplification, which determines the fusion effect and antibody production. Here we compared the growth and survival rates of hybridoma in a commonly used peritoneal macrophage feeder layer (PMFL) nutrition supply system with a commercial hybridoma feeder additive (HFA) nutrition supply system at the post fusion stage and discussed the titer of monoclonal antibodies by enzyme linked immunosorbent assay (ELISA). Our results indicate that commercially available HFA promotes the survival and amplification of hybridoma clones and improves the titer of monoclonal antibodies indirectly.

     

    • FullText(HTML)
  • loading
    • References(32)
  • [1]
    Zaroff S, Tan G. Hybridoma technology: the preferred method for monoclonal antibody generation for in vivo applications[J]. Biotechniques, 2019, 67(3): 90−92. doi: 10.2144/btn-2019-0054
    [2]
    Bayer V. An overview of monoclonal antibodies[J]. Semin Oncol Nurs, 2019, 35(5): 150927. doi: 10.1016/j.soncn.2019.08.006
    [3]
    Nimmerjahn, Falk. Regulation of immunological responses by the neonatal Fc receptor for IgG, FcRn[M]//Springer. New York: Molecular and cellular mechanisms of antibody activity, 2013: 189–219.
    [4]
    Heyman B. Regulation of antibody responses via antibodies, complement, and Fc receptors[J]. Annu Rev Immunol, 2000, 18(1): 709−737. doi: 10.1146/annurev.immunol.18.1.709
    [5]
    Cyster JG, Allen C. B cell responses: cell interaction dynamics and decisions[J]. Cell, 2019, 177(3): 524−540. doi: 10.1016/j.cell.2019.03.016
    [6]
    Nelson PN, Reynolds GM, Waldron EE, et al. Monoclonal antibodies[J]. Mol Pathol, 2000, 53(3): 111−117. doi: 10.1136/mp.53.3.111
    [7]
    Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer[J]. Hematol Oncol Clin North Am, 2012, 26(3): 447−481. doi: 10.1016/j.hoc.2012.02.013
    [8]
    Pento JT. Monoclonal antibodies for the treatment of cancer[J]. Anticancer Res, 2017, 37(11): 5935−5939. doi: 10.21873/anticanres.12040
    [9]
    Hanack K, Messerschmidt K, Listek M. Antibodies and selection of monoclonal antibodies[J]. Adv Exp Med Biol, 2016, 917: 11−22. doi: 10.1007/978-3-319-32805-8_2
    [10]
    Van Koecke L, Roose K. How mRNA therapeutics are entering the monoclonal antibody field[J]. J Transl Med, 2020, 17(1): 54. doi: 10.1186/s12967-019-1804-8
    [11]
    Zhang CH. Hybridoma technology for the generation of monoclonal antibodies[J]. Methods Mol Biol, 2012, 901: 117−135. doi: 10.1007/978-1-61779-931-0_7
    [12]
    Zhang RJ, Prabakaran P, Yu X, et al. A platform-agnostic, function first-based antibody discovery strategy using plasmid-free mammalian expression of antibodies[J]. MAbs, 2021, 13(1): 1904546. doi: 10.1080/19420862.2021.1904546
    [13]
    Zhang Y, Cao P, Lu F, et al. Generation of monoclonal antibodies against natural products[J]. J Vis Exp, 2019, 6(146).
    [14]
    Khongorzul P, Ling CJ, Khan FU, et al. Antibody-drug conjugates: a comprehensive review[J]. Mol Cancer Res, 2020, 18(1): 3−19. doi: 10.1158/1541-7786.MCR-19-0582
    [15]
    Mould DR, Meibohm B. Drug development of therapeutic monoclonal antibodies[J]. BioDrugs, 2016, 30(4): 275−293. doi: 10.1007/s40259-016-0181-6
    [16]
    Ritter MA. Polyclonal and monoclonal antibodies[J]. Methods Mol Med, 2000, 40: 23−34. doi: 10.1385/1-59259-076-4:23
    [17]
    Ali MG, Zhang Z, Gao Q, et al. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview[J]. Immunol Res, 2020, 68(6): 325−339. doi: 10.1007/s12026-020-09159-z
    [18]
    McGuire AT. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design[J]. Curr Opin HIV AIDS, 2019, 14(4): 294−301. doi: 10.1097/COH.0000000000000548
    [19]
    Zhang ZB, Liu HJ, Guan Q, et al. Advances in the isolation of specific monoclonal rabbit antibodies[J]. Front Immunol, 2017, 8: 494. doi: 10.3389/fimmu.2017.00494
    [20]
    Harbour C, Barford JP, Low KS. Process development for hybridoma cells[J]. Adv Biochem Eng Biotechnol, 1988, 37: 1−40. doi: 10.1007/BFb0009175
    [21]
    Elgundi Z, Reslan M, Cruz E, et al. The state-of-play and future of antibody therapeutics[J]. Adv Drug Deliv Rev, 2017, 122: 2−19. doi: 10.1016/j.addr.2016.11.004
    [22]
    Sepúlveda DE, Meckert PC, Locatelli P, et al. Activated macrophages as a feeder layer for growth of resident cardiac progenitor cells[J]. Cytotechnology, 2016, 68(4): 665−674. doi: 10.1007/s10616-014-9814-0
    [23]
    Hoffmann P, Jiménez-Diaz M, Weckesser J, et al. Murine bone marrow-derived macrophages constitute feeder cells for human B cell hybridomas[J]. J Immunol Methods, 1996, 196(1): 85−91. doi: 10.1016/0022-1759(96)00121-4
    [24]
    Shimizu S. The mechanisms of myeloma cell growth[J]. Nihon Rinsho (in Japanese), 1995, 53(3): 557–563.
    [25]
    Itagaki H, Doi H, Ohkohchi N, et al. Development of new cell fusion technique by laser device and application to bio-medical field[J]. Nihon Rinsho (in Japanese), 1997, 55(10): 2780–2787.
    [26]
    Fujiwara N, Kobayashi K. Macrophages in inflammation[J]. Curr Drug Targets Inflamm Allergy, 2005, 4(3): 281−286. doi: 10.2174/1568010054022024
    [27]
    Greenfield EA. Single-cell cloning of hybridoma cells by growth in soft agar[J]. Cold Spring Harbor Protoc, 2019, 2019(11).
    [28]
    Bougie DW, Sutton J, Aster RH. Characterization of glycoprotein IIb/IIIa‐specific alloantibodies induced by cross‐strain platelet immunization in mice[J]. Transfusion, 2021, 61(4): 1278−1285. doi: 10.1111/trf.16275
    [29]
    Unterkircher CS, Leão MV, Carvalho YR, et al. Immunization of balb/c mice with modified auto- antigens for induction of autoimmune sialoadenitis[J]. 2007, 18(1): 40–44.
    [30]
    Greenfield EA. Preparing feeder cell cultures to support hybridoma growth[J]. Cold Spring Harbor Protoc, 2019, 2019(11).
    [31]
    Mikami T, Makishima F, Suzuki E. Enhancing effect of mouse peritoneal exudate cells and their products on antibody productivity of hybridoma cells: application of in vivo factors to in vitro culture[J]. Cytotechnology, 1991, 7(2): 93−101. doi: 10.1007/BF00350915
    [32]
    Brodin T, Olsson L, Sjögren HO. Cloning of human hybridoma, myeloma and lymphoma cell lines using enriched human monocytes as feeder layer[J]. J Immunol Methods, 1983, 60(1-2): 1−7. doi: 10.1016/0022-1759(83)90329-0
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2077) PDF downloads(15) Cited by()
    Proportional views
    Related

    Copyright © Blood and Genomics苏公网安备 32028102000501号苏ICP备14047883号-6

    Address：Rooms 1318-19, Hollywood Plaza, 610 Nathan Road, Mongkok, Kowloon, HongKong

    E-mail：editorial_office@apjbg.com

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return